Linkage of 10q22-q23 to schizophrenia and the recently reported association of Neuregulin 3 (NRG3) polymorphisms with high 'delusion factor' scores led us to attempt replication and further refinement of these findings in a sample of 411 schizophrenic patients and 223 nonpsychiatric control subjects. Using quantitative cognitive traits, patients were grouped into a cluster with pervasive cognitive deficit (CD) and a cluster with relatively spared cognition (CS). We found a significant association between rs6584400 and schizophrenia, with a trend for rs10883866. Post hoc analysis revealed that this result was mainly due to the CS cluster, characterized by elevated scores on Schneiderian first-rank symptoms, salience of complex delusions and positive thought disorder-thus closely related to the 'delusion factor'. In addition, both rs6584400 and rs10883866 were associated with the degraded-stimulus continuous performance task in which 'risk' alleles were associated with better than average performance in patients and worse performance in controls. This suggests that NRG3 may be modulating early attentional processes for perceptual sensitivity and vigilance, with opposite effects in affected individuals and healthy controls. The two single-nucleotide polymorphisms are in close proximity to the alternative first exons of the NRG3-a, -b and -d isoforms, of which the human brain-specific NRG-b appears to be the most interesting candidate.
Introduction
The Neuregulin family of growth and differentiation factors (NRG1-4) 1,2 and their cognate ErbB receptor tyrosine kinases have multiple roles in brain development and neuronal and glial maturation and function. 3, 4 By far, the best studied member of the family is NRG1, a large protein with numerous functional domains and an astonishing diversity of isoforms, 4 in which variation in the 5 0 region has been implicated in schizophrenia susceptibility, with the expression of some brain-specific isoforms differentially regulated by associated upstream polymorphisms. [5] [6] [7] The involvement of Neuregulin 3 (NRG3) in psychiatric illness was first suggested by linkage of schizophrenia to chromosome 10q22-q23 in Ashkenazim and Han Chinese families 8, 9 and by the detection of complex 10q22-q23 rearrangements in several families with cognitive and behavioral abnormalities. 10 Further support was provided by reports of association between single-nucleotide polymorphisms (SNPs) in NRG3 and schizophrenia in Scottish 11 and Han Chinese 12 samples and, recently, by comprehensive association mapping of the linked 10q22-q23 region in Ashkenazi case-control and family-based samples. 1 The latter study found no evidence of association with the broad phenotype of the Diagnostic and Statistical Mannual of Mental Disorders, Fourth Edition (DSM-IV) schizophrenia; however, factor analysis disaggregation of the clinical phenotype 2 identified the association between a 'delusion factor' and sequence variants (rs10883866 and rs6584400) in intron 1 of the NRG3 gene. Another recent study, focusing on rare copy-number variants in familial schizophrenia, reported a 73.6 kb duplication in the first intron of NRG3 segregating to all affected family members, thus highlighting this gene as 'particularly worthy of follow-up'. 13 Our linkage analysis in the Western Australian Family Study of Schizophrenia 14 ranked the 10q22-q23 region among its most significant findings, in which the linked marker D10S1686 is located B1.9 Mb from NRG3. In this study, we aimed at replicating the Chen et al. 1 findings in a schizophrenia case-control sample of Anglo-Irish background, and at investigating the potential effects of the associated variants on neurocognitive endophenotypes.
Materials and methods

Subjects
A total of 411 schizophrenic patients were recruited from admissions to a major psychiatric hospital and community-based mental health services in Western Australia. Diagnostic assessment included structured interviews using the Schedules for Clinical Assessment in Neuropsychiatry 15 or the Diagnostic Interview for Psychoses, 16 a review of case records, and a structured developmental history. Research diagnoses (lifetime) according to the International Classification of Diseases, Tenth Revision (ICD-10) and DSM-IV criteria were assigned by two senior clinicians who reviewed all relevant information, including the video record of the diagnostic interview. The nonpsychiatric control participants (N = 223) were recruited from the registry of Red Cross blood donors or by random sampling from local telephone directories. Inclusion of controls was based on a psychiatric screening interview and required absence of psychotic illness in the individual and in first-degree relatives, as well as absence of a history of substance dependence, brain trauma or neurological disease. All participants were unrelated and were of European descent ( > 75% Anglo-Irish). The study was approved by the Human Research Ethics Committees of the University of Western Australia and the North Metropolitan Area Health Service in Perth, Western Australia.
The 634 subjects in our sample underwent extensive neurocognitive testing with a battery of neurocognitive tests examining general cognitive ability (premorbid and current IQ), learning and episodic verbal memory, executive function, speed of information processing and focused sustained attention.
14 A form of latent structure analysis (Grade of Membership, GoM; 17 Supplementary Methods) was used to identify a parsimonious number of multivariate patterns of test responses ('pure types') and to simultaneously tag each individual's degree of affinity to those patterns with a set of grade of membership scores (constrained to range from 0 to 1). 14 Grouping the subjects by their highest membership scores for a given pure type yielded two relatively homogeneous clusters: one of the cases with pervasive cognitive deficit (CD, N = 180), and another, comprising cases with relatively spared cognition (CS, N = 148). The remainder fell into a non-CD/non-CS subgroup (N = 83), which consisted almost exclusively of patients aged X45 years with circumscribed mild deficits (mainly reduced information processing speed) attributable to aging. These non-CD/non-CS subjects were included only in the schizophrenia case-control comparisons. Demographic features and cognitive profiles of the schizophrenia cases, CD/CS clusters and control subjects are given in Supplementary Table 2 .
Genotyping All participants were genotyped for the SNPs that showed the strongest evidence of association in the Chen et al.
1 study, rs10883866 and rs6584400. These two SNPs were genotyped with 5 0 -exonuclease allelic discrimination assays (Taqman SNP genotyping assays) according to the protocol of Applied Biosystems (Applied Biosystems, Foster City, CA, USA). After quality control and cleaning of the genotyping data, the number of samples available for the statistical analyses was 395 schizophrenia cases (171 CD, 144 CS, 80 non-CD/non-CS) and 221 controls for rs10883866, and 391 cases (169 CD, 143 CS, 79 non-CD/non-CS) and 220 controls for rs6584400.
Statistical analyses
Statistical analyses were performed using PLINKv1.06. 18 We used the w 2 goodness-of-fit test (one degree of freedom) for the initial single-marker allelic association analysis with schizophrenia in the entire case-control sample, and for the post hoc analyses with the CD and CS clusters. Analysis of allelic association with the quantitative cognitive traits was conducted using linear regression as implemented in PLINK. In addition, association between the marker, disease status and the cognitive phenotypes was investigated using a generalized linear model framework with SPSSv17 (SPSS Inc., Chicago, IL, USA). The scores for each cognitive test (standardized IQ points for the general intelligence tests; raw scores for the memory and attention tests) were entered as dependent variables, NRG3 genotypes and diseases status as fixed factors, and where appropriate, age, sex and education as covariates.
Results
Association with schizophrenia
The initial statistical analysis tested for allelic association of each SNP with the binary phenotype of schizophrenia. Unlike the Ashkenazi sample, 1 we did obtain evidence of association between rs6584400 and schizophrenia, with an odds ratio 1.45 (95% confidence interval (CI) 1.03-2.04) and P = 0.03 for the minor allele (A), whereas SNP rs10883866 showed a trend in the same direction without reaching nominal significance, odds ratio 1.36 (0.95-1.94), P = 0.10 (Table 1) .
Association with case clusters based on cognitive patterns To obtain a closer comparison to the findings of association with the 'delusion factor', 1 we further examined the association between the two polymorphisms and the two major schizophrenia case clusters in our sample. Previous analyses 14, 19, 20 have shown CD cases to be characterized by higher scores NRG3 and schizophrenia B Morar et al on poverty of thought, flat or incongruous effect, paucity of complex delusions, and poor social functioning, whereas CS patients presented with higher scores on Schneiderian first-rank symptoms, florid and often complex delusions, and positive thought disorder. The CD and CS case clusters were tested for association with rs6584400 and rs10883866. The results indicated that the association with schizophrenia in the overall case-control sample was in fact due to association with the CS cluster: rs6584400 odds ratio 1.67 (1.10-2.53), P = 0.02, and a trend for rs10883866 odds ratio 1.49 (0.96-2.32), P = 0.07. No significant results were obtained in the analysis of the CD cluster ( Table 1) .
The parallels between the characteristics of our CS cluster and the Chen et al. 1 'delusion factor', also based mostly on first-rank symptoms, 2 suggest a common interpretation of the genetic association findings in the two studies, namely, a contribution of NRG3 sequence variants to a subtype of schizophrenia with relatively preserved cognitive function but prone to florid and complex delusions.
Association with individual cognitive traits
To dissect further the contribution of NRG3 sequence polymorphisms to the schizophrenia phenotype, we examined the allelic association of the two SNPs with quantitative traits indexing performance in several cognitive domains, with a differential contribution to the CD/CS clusters. 14 We found no effect on general intelligence or verbal memory (Supplementary Table 1 ). This is in agreement with our previous finding that high scores on Schneiderian 21 first-rank symptoms are correlated with relatively better performance on cognitive tasks. 20 By contrast, there was a significant association of the minor alleles of the SNPs (G for rs10883866 and A for rs6584400), in both cases and controls with the discrimination (signal detection) index dL of the degraded-stimulus continuous performance task (CPT-DS). 22 Under the additive model, assumed in the allelic association test, the minor alleles were associated with better performance in schizophrenic patients (P = 0.007, b = 0.687 (95% CI 0.195-1.178) for rs10883866, and P = 0.025, b = 0.523 (95% CI 0.070-0.976) for rs6584400) and poorer performance in healthy controls (P = 0.006, b = À0.622 (95% CI À1.053 to À0.192) for rs10883866, and P = 0.006, b = À0.548 (95% CI À0.934 to À0.163) for rs6584400). The CPT-DS test requires attentional focus on rapidly paced, partially degraded visual stimuli (blurred digits). The task engages medial superior frontal and inferior temporal regions; 23 it demands vigilance, prompt perceptual analysis and efficient signal/noise discrimination. CPT-DS performance is stable over time, not state dependent and relatively uninfluenced by antipsychotic medication. With an estimated heritability at 0.57, it meets the criteria for an endophenotype. 24 The effects of the associated minor ('risk') alleles of the two polymorphisms on different measures of cognitive performance were examined further using generalized linear models. This analysis confirmed the effect of the schizophrenia 'risk' alleles on significantly improved CPT-DS performance in patients (P = 0.013 for rs10883866; P = 0.043 for rs6584400) and significantly worse performance in controls (P = 0.012 for rs10883866; P = 0.023 for rs6584400) (Figure 1 ; Table 2 ). The effect size (and group mean) for CPT-DS reaction time is significant for rs6584400 in the schizophrenia group, and Significant results are shown in bold typeface. Figure 1 Mean CPT-DS/dL test scores in schizophrenia cases and controls, stratified by genotypes at rs10883866. A very similar trend is seen for rs6584400 (not shown).
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indicates faster response times in the risk allele carriers compared with non-carriers, consistent with the improved CPT performance in this group. We examined and excluded differential test response bias between cases and controls as an explanation of these observations (data not shown). Furthermore, none of the covariates had a significant effect on the CPT-DS discrimination index dL, (age was only associated with CPT-DS reaction time). At the case cluster level, a considerable performance gain (improved CPT-DS discrimination index) was statistically significant for the cognitively more impaired CD cases, but a trend in the same direction was also present in the CS cases. Effect sizes (Cohen's d) for these associations are in the medium to high range (0.37-0.62).
Discussion
Our study replicates previously reported findings of association between SNPs within NRG3 and the clinical phenotype of schizophrenia, and extends these results by showing that the association with rs6584400 and rs10883866 is mainly driven by a subset of schizophrenia cases characterized by relatively spared cognition, florid delusions and Schneiderian first-rank symptoms (no association was found with cases exhibiting pervasive CD). A novel finding of potential interest, revealed by analysis of individual cognitive traits, is the significant statistical interaction of the two associated SNPs with signal/ noise discrimination on the CPT-DS, in which cases and controls carrying the minor ('risk') alleles show exactly opposite test performance trends: improvement (normalization) in cases and worsening (deterioration) in controls. This observation is strongly suggestive of an inverted U-curve dose-response pattern, a well-known phenomenon described previously in studies of prefrontal cortex neuronal excitability in response to varying concentrations of dopamine associated with the val/met polymorphisms in the COMT gene. 25 Inverted-U response patterns have also been reported for the effects of dopamine D1 receptor stimulation on spatial working memory, 26 and for calcineurin overexpression on the transition from short-to long-term memory. 27 The seemingly paradoxical impact of the minor alleles of rs10883866 and rs6584400 on CTP-DS in schizophrenia cases and healthy controls is therefore compatible with 'supranormal' expression of a gene product that boosts cognitive performance in individuals with preexisting deficiency, but affects adversely individuals functioning at 'peak' level by tipping them over into the descending arm of the inverted U. A caveat to this interpretation is that the leap from genetic association with a neurocognitive endophenotype to functional effects of the associated variants on a specific gene/protein function is problematic in the case of NRG3, whose biological roles remain unclear. NRG3 is abundantly expressed in the developing and adult brain. 28, 29 The encoded transmembrane protein differs from other members of the NRG family (including NRG1) in a number of structural and functional characteristics, which suggest distinct nonoverlapping functions. 29 The extracellular part contains an epidermal growth factor (EGF)-like domain (31% identity with the NRG1 EGF-like domain). It does not contain Ig-like or kringle domains, and instead has a unique Ala/Gly-rich region with multiple sites for O-linked glycosylation. The putative intracellular domain (ICD) shows only 13% sequence identity to the NRG1 ICD. Finally, NRG3 binds to the ErbB4 receptor tyrosine kinase, but is not an ErbB2-and ErbB3-ligand. isoforms, with eight alternative transcripts currently listed in the NCBI AceView. The associated SNPs rs10883866 and rs6584400 are located B13 kb apart and close to the alternative first exons of NRG3-a, -b and -d (Figure 2 ), pointing to possible involvement in the regulation of the expression or the alternative splicing of these isoforms. Our examination of NRG3 expression data (BioGPS 30 ) and bioinformatics analysis indicate that the NRG3-a transcript (detected by reporter gnf1h05312) is widely expressed with no evidence of tissue specificity, whereas transcripts NRG3-b and NRG3-d (reporter gnf1h10765) show markedly higher expression in fetal and adult brain, especially in the amygdala, prefrontal cortex and cingulate cortex. NRG-b was originally described by Carteron et al. 31 as a fetal brain-specific isoform, containing novel primate-specific exons. Our bioinformatics analysis showed that the first two alternative exons of NRG3-b and NRG3-d (numbered exons 2, 3 and 5 in Figure 2 ) are absent from the expressed sequence tag (EST) databases of chimpanzee, rhesus monkey and rodents, and thus appear to be human specific. Open reading frame and protein homology analysis indicated that translation of NRG3-b starts from exon 2 (unlike the NRG3-d transcript, where it does not start until exon 10), producing a 499 amino-acid protein, whose unique 53 amino-acid N-terminal sequence has no similarity to other currently known eukaryotic proteins. These data make NRG3-b a particularly interesting isoform with possibly novel neuronal functions that may be modulated by the associated polymorphisms or by another correlated variant. Bioinformatics analyses do not predict any changes, caused by the associated SNP alleles, in transcription factor-binding sites or splicing regulation. SNPs rs10883866 and rs6584400 are however located within an linkage disequilibrium (LD) block, spanning the alternative NRG3 promoters and first exons, and part of intron 1. The association signal is thus likely to flag a functional variant elsewhere in this region that should be further investigated.
Overall, our results are compatible with the proposition that the schizophrenia phenotype comprises heterogeneous components, 2, 19 influenced by multiple genetic loci that modulate the signs and symptoms of the disorder indirectly through complex interactions at neural circuitry level that could be further dissected with the aid of neurocognitive endophenotypes and correlated clinical features. NRG3 appears to be a prime candidate for this approach.
